Abeona Therapeutics Inc. - Common Stock (ABEO)

This company is making excellent progress on its treatment for a very rare and serious skin disorder.

Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.

Let's have a look at the gap up and gap down stocks in today's session.

Abeona Therapeutics beat Q3 EPS estimates but missed on revenue. The stock fell as investors focus on the delayed launch of its new gene therapy, ZEVASKYN.

Let's have a look at what is happening on the US markets on Thursday. Below you can find the stocks with an unusual volume in today's session.

Intrigued by the market activity one hour before the close of the markets on Wednesday? Uncover the key winners and losers of today's session in our insightful analysis.

Abeona's Zevaskyn secures timely FDA nod, priced at $3.1 million, with 2025 sales now forecast at $31.6 million and peak U.S. revenue projected at $600 million.

Abeona shares are trading higher on Wednesday on possible continued strength after the FDA announced approval for its gene therapy.

Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

FDA approves Zevaskyn as the first cell-based gene therapy for RDEB wounds after strong results in pivotal and long-term studies.

ZEVASKYN is expected to be available beginning in the third quarter of 2025 through ZEVASKYN Qualified Treatment Centers, located across the U.S. with experience in cell and gene therapy.

ABEO stock results show that Abeona Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

ABEO stock results show that Abeona Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.